Business Wire

Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry

NEW YORK--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on ...
Business Insider

AnaPath Services Acquires Envigo CRS S.A.U. in Barcelona to provide full services in non-clinical safety assessment for chemical and pharmaceutical industries

GENEVA, Nov. 21, 2019 /CNW/ -- AnaPath Services GmbH, the Swiss CRO specialized in histopathology, has acquired legacy Envigo CRS S.A.U. a CRO for non-clinical safety assessment on November 5 th, 2019 ...
Stockhouse

Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on allogeneic gene edited CAR T-cells (UCART), ...